Earnings Release: Here's Why Analysts Cut Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target To US$26.67
Earnings Release: Here's Why Analysts Cut Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target To US$26.67
Investors in Fulgent Genetics, Inc. (NASDAQ:FLGT) had a good week, as its shares rose 4.4% to close at US$21.49 following the release of its first-quarter results. It looks like the results were pretty good overall. While revenues of US$64m were in line with analyst predictions, statutory losses were much smaller than expected, with Fulgent Genetics losing US$0.45 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Fulgent Genetics, Inc.(納斯達克股票代碼:FLGT)的投資者度過了愉快的一週,在公佈第一季度業績後,其股價上漲了4.4%,收於21.49美元。總體而言,結果似乎相當不錯。儘管6400萬美元的收入與分析師的預測一致,但法定虧損遠小於預期,Fulgent Genetics每股虧損0.45美元。根據結果,分析師更新了他們的盈利模式,很高興知道他們是否認爲公司的前景發生了巨大變化,或者業務是否照舊。考慮到這一點,我們收集了最新的法定預測,以了解分析師對明年的預期。
Taking into account the latest results, the current consensus, from the three analysts covering Fulgent Genetics, is for revenues of US$280.2m in 2024. This implies a measurable 2.6% reduction in Fulgent Genetics' revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 52% to US$2.67. Before this earnings announcement, the analysts had been modelling revenues of US$279.4m and losses of US$2.31 per share in 2024. So it's pretty clear the analysts have mixed opinions on Fulgent Genetics even after this update; although they reconfirmed their revenue numbers, it came at the cost of a considerable increase in per-share losses.
考慮到最新結果,負責Fulgent Genetics的三位分析師目前的共識是,2024年的收入爲2.802億美元。這意味着在過去的12個月中,Fulgent Genetics的收入減少了2.6%。預計損失將大幅下降,萎縮52%,至2.67美元。在此業績公佈之前,分析師一直在模擬2024年的收入爲2.794億美元,每股虧損爲2.31美元。因此,很明顯,即使在這次更新之後,分析師對Fulgent Genetics的看法也參差不齊;儘管他們重申了收入數字,但這是以每股虧損大幅增加爲代價的。
The consensus price target fell 14% to US$26.67per share, with the analysts clearly concerned by ballooning losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Fulgent Genetics, with the most bullish analyst valuing it at US$30.00 and the most bearish at US$25.00 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
共識目標股價下跌14%,至每股26.67美元,分析師顯然對虧損激增感到擔憂。但是,這並不是我們可以從這些數據中得出的唯一結論,因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。對Fulgent Genetics的看法有所不同,最看漲的分析師將其估值爲30.00美元,最看跌的爲每股25.00美元。由於估值範圍如此狹窄,分析師顯然對他們認爲的業務價值有相似的看法。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 3.4% annualised decline to the end of 2024. That is a notable change from historical growth of 22% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 6.7% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Fulgent Genetics is expected to lag the wider industry.
了解這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。我們要強調的是,收入預計將逆轉,預計到2024年底年化下降3.4%。與過去五年22%的歷史增長相比,這是一個顯著的變化。相比之下,我們的數據表明,在可預見的將來,預計同一行業的其他公司(有分析師報道)的收入每年將增長6.7%。因此,儘管預計其收入將萎縮,但這種陰雲並沒有帶來一線希望——預計Fulgent Genetics將落後於整個行業。
The Bottom Line
底線
The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Fulgent Genetics' revenue is expected to perform worse than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
要了解的最重要的一點是,分析師提高了明年的每股虧損預期。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,預計Fulgent Genetics的收入表現將比整個行業差。此外,分析師還下調了目標股價,這表明最新消息加劇了人們對業務內在價值的悲觀情緒。
With that in mind, we wouldn't be too quick to come to a conclusion on Fulgent Genetics. Long-term earnings power is much more important than next year's profits. We have forecasts for Fulgent Genetics going out to 2026, and you can see them free on our platform here.
考慮到這一點,我們不會太快就Fulgent Genetics得出結論。長期盈利能力比明年的利潤重要得多。我們對Fulgent Genetics的預測將持續到2026年,你可以在我們的平台上免費查看。
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
需要考慮的另一件事是管理層和董事最近是否在買入或賣出股票。我們在此處概述了過去十二個月在我們的平台上所有公開市場股票交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。